Abstract 634P
Background
CTS2190 could specifically inhibit type I protein arginine methyltransferases (PRMTs) and significantly reduce intra-tumor asymmetric dimethylarginine (ADMA) level and oncogenic proliferation by epigenetic modulation, RNA splicing, DNA damage as well as remarkable cancer immune activation in various solid and/or hematological cancers. Here we report the dose escalation results from an ongoing first-in-human phase I/II study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of CTS2190 in patients (pts) with advanced solid tumors.
Methods
Eligible pts were enrolled in escalating dose cohorts (60 to 240 mg) administered orally until progression or unacceptable toxicity. The accelerated titration combined with Bayesian optimal interval (BOIN) design was used as the dose escalation schedule.
Results
As of Apr 2, 2024, 15 pts including 10 non-small cell lung cancer (NSCLC), 1 colorectal cancer (CRC),1 triple-negative breast cancer (TNBC), 2 head and neck squamous cell carcinoma (HNSCC) and 1 esophageal squamous cell carcinoma (ESCC) received CTS2190 treatment. Among them, 9 pts received ≥3 lines of prior therapy. Treatment-related adverse events (TRAEs) of ≥Grade 3 were platelet count decreased (33.3%), amylase increased (6.7%) and blood creatine phosphokinase increased (6.7%). Dose-limiting toxicity (DLT) was observed in 1 pt (in 240 mg) who continued treatment after dose reduction. No TRAEs led to treatment discontinuation or death. Of the 10 response-evaluable pts (>60 mg), the objective response rate (ORR) and disease control rate (DCR) were 20.0% and 70.0% respectively. In the subset of NSCLC pts, the ORR and DCR were 40.0% and 60.0% respectively. Exposure of CTS2190 increased proportionally with increasing dose. Time- and dose-dependent pharmacodynamics (PD) changes in circulating free ADMA, monomethylarginine (MMA) and symmetric dimethylarginine (SDMA) were also observed.
Conclusions
CTS2190 was well tolerated and showed encouraging antitumor activities in advanced and/or metastatic solid tumors, including NSCLC, TNBC, HNSCC and ESCC. Further investigation of CTS2190 in larger pts population is ongoing including biomarker exploration.
Clinical trial identification
NCT06224387.
Editorial acknowledgement
Legal entity responsible for the study
CytosinLab Therapeutics Co., Ltd.
Funding
CytosinLab Therapeutics Co., Ltd.
Disclosure
J. Miao, Y. Mi, S. Xing, H. Wu: Financial Interests, Personal and Institutional, Full or part-time Employment: CytosinLab Therapeutics Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
652P - BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Presenter: Oscar Reig Torras
Session: Poster session 01
653P - A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
Presenter: Matthew Chau Hsien Ng
Session: Poster session 01
654P - Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors
Presenter: Bernard Doger de Spéville
Session: Poster session 01
655P - Toxicity and efficacy of antibody drug conjugates (ADC) in advanced solid tumors: A pooled analysis of Sarah Cannon UK
Presenter: Rachel Woodford
Session: Poster session 01
656P - Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Presenter: Victor Moreno Garcia
Session: Poster session 01
657P - Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
Presenter: Noé Herbel
Session: Poster session 01
658P - First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Cátia Fava Gaspar
Session: Poster session 01
659P - Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer
Presenter: Zev Wainberg
Session: Poster session 01
660P - Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study
Presenter: Laura Mansi
Session: Poster session 01
661P - Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial
Presenter: Barend Sikkema
Session: Poster session 01